227 related articles for article (PubMed ID: 29584544)
21. Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib.
Jain P; Keating M; Wierda W; Estrov Z; Ferrajoli A; Jain N; George B; James D; Kantarjian H; Burger J; O'Brien S
Blood; 2015 Mar; 125(13):2062-7. PubMed ID: 25573991
[TBL] [Abstract][Full Text] [Related]
22. Chemoimmunotherapy Versus Targeted Treatment in Chronic Lymphocytic Leukemia: When, How Long, How Much, and in Which Combination?
Brown JR; Hallek MJ; Pagel JM
Am Soc Clin Oncol Educ Book; 2016; 35():e387-98. PubMed ID: 27249745
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: an open-label, randomised phase 3 trial.
Jones JA; Robak T; Brown JR; Awan FT; Badoux X; Coutre S; Loscertales J; Taylor K; Vandenberghe E; Wach M; Wagner-Johnston N; Ysebaert L; Dreiling L; Dubowy R; Xing G; Flinn IW; Owen C
Lancet Haematol; 2017 Mar; 4(3):e114-e126. PubMed ID: 28257752
[TBL] [Abstract][Full Text] [Related]
24. Targeting neoplastic B cells and harnessing microenvironment: the "double face" of ibrutinib and idelalisib.
Maffei R; Fiorcari S; Martinelli S; Potenza L; Luppi M; Marasca R
J Hematol Oncol; 2015 May; 8():60. PubMed ID: 26022368
[TBL] [Abstract][Full Text] [Related]
25. Pharmacotherapeutic Management of Chronic Lymphocytic Leukaemia in Patients with Comorbidities: New Agents, New Hope.
Goede V; Hallek M
Drugs Aging; 2015 Nov; 32(11):877-86. PubMed ID: 26446155
[TBL] [Abstract][Full Text] [Related]
26. Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib.
Awan FT; Schuh A; Brown JR; Furman RR; Pagel JM; Hillmen P; Stephens DM; Woyach J; Bibikova E; Charuworn P; Frigault MM; Hamdy A; Izumi R; Linghu B; Patel P; Wang MH; Byrd JC
Blood Adv; 2019 May; 3(9):1553-1562. PubMed ID: 31088809
[TBL] [Abstract][Full Text] [Related]
27. Ibrutinib, idelalisib and obinutuzumab for the treatment of patients with chronic lymphocytic leukemia: three new arrows aiming at the target.
Morabito F; Gentile M; Seymour JF; Polliack A
Leuk Lymphoma; 2015; 56(12):3250-6. PubMed ID: 26062943
[TBL] [Abstract][Full Text] [Related]
28. Novel agents in the treatment of chronic lymphocytic leukemia: a review about the future.
Desai AV; El-Bakkar H; Abdul-Hay M
Clin Lymphoma Myeloma Leuk; 2015 Jun; 15(6):314-22. PubMed ID: 25445466
[TBL] [Abstract][Full Text] [Related]
29. Idelalisib for the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma.
Barrientos JC
Future Oncol; 2016 Sep; 12(18):2077-94. PubMed ID: 27324214
[TBL] [Abstract][Full Text] [Related]
30. Chronic lymphocytic leukaemia: the role of T cells in a B cell disease.
Man S; Henley P
Br J Haematol; 2019 Jul; 186(2):220-233. PubMed ID: 30945268
[TBL] [Abstract][Full Text] [Related]
31. Pharmacovigilance during ibrutinib therapy for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) in routine clinical practice.
Finnes HD; Chaffee KG; Call TG; Ding W; Kenderian SS; Bowen DA; Conte M; McCullough KB; Merten JA; Bartoo GT; Smith MD; Leis J; Chanan-Khan A; Schwager SM; Slager SL; Kay NE; Shanafelt TD; Parikh SA
Leuk Lymphoma; 2017 Jun; 58(6):1376-1383. PubMed ID: 27820970
[TBL] [Abstract][Full Text] [Related]
32. Targeted therapy in the treatment of chronic lymphocytic leukemia: facts, shortcomings and hopes for the future.
Molica S
Expert Rev Hematol; 2017 May; 10(5):425-432. PubMed ID: 28349723
[TBL] [Abstract][Full Text] [Related]
33. The role of B-cell receptor inhibitors in the treatment of patients with chronic lymphocytic leukemia.
Wiestner A
Haematologica; 2015 Dec; 100(12):1495-507. PubMed ID: 26628631
[TBL] [Abstract][Full Text] [Related]
34. B cell receptor inhibition as a target for CLL therapy.
Jeyakumar D; O'Brien S
Best Pract Res Clin Haematol; 2016 Mar; 29(1):2-14. PubMed ID: 27742069
[TBL] [Abstract][Full Text] [Related]
35. Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia.
Brown JR; Byrd JC; Coutre SE; Benson DM; Flinn IW; Wagner-Johnston ND; Spurgeon SE; Kahl BS; Bello C; Webb HK; Johnson DM; Peterman S; Li D; Jahn TM; Lannutti BJ; Ulrich RG; Yu AS; Miller LL; Furman RR
Blood; 2014 May; 123(22):3390-7. PubMed ID: 24615777
[TBL] [Abstract][Full Text] [Related]
36. Long-term Efficacy of Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia: Results of the Polish Adult Leukemia Study Group Observational Study.
Pula B; Iskierka-Jazdzewska E; Dlugosz-Danecka M; Szymczyk A; Hus M; Szeremet A; Drozd-Sokolowska J; Waszczuk-Gajda A; Zaucha JM; Holojda J; Piszczek W; Steckiewicz P; Wojciechowska M; Osowiecki M; Knopinska-Posluszny W; Dudzinski M; Zawirska D; Subocz E; Halka J; Pluta A; Wichary R; Kumiega B; Budziszewska BK; Jurczak W; Lech-Maranda E; Giannopoulos K; Robak T; Jamroziak K
Anticancer Res; 2020 Jul; 40(7):4059-4066. PubMed ID: 32620653
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of the CLL-IPI in relapsed and refractory chronic lymphocytic leukemia in idelalisib phase-3 trials.
Soumerai JD; Ni A; Xing G; Huang J; Furman RR; Jones J; Sharman JP; Hallek M; Adewoye AH; Dubowy R; Dreiling L; Zelenetz AD
Leuk Lymphoma; 2019 Jun; 60(6):1438-1446. PubMed ID: 30407886
[TBL] [Abstract][Full Text] [Related]
38. Advances in the treatment of relapsed/refractory chronic lymphocytic leukemia.
Shustik C; Bence-Bruckler I; Delage R; Owen CJ; Toze CL; Coutre S
Ann Hematol; 2017 Jul; 96(7):1185-1196. PubMed ID: 28389687
[TBL] [Abstract][Full Text] [Related]
39. B-cell receptor inhibitors in chronic lymphocytic leukemia.
Flinn IW
Clin Adv Hematol Oncol; 2011 Aug; 9(8):605-6. PubMed ID: 22236988
[No Abstract] [Full Text] [Related]
40. Retrospective Analysis of the Impact of Adverse Event-Triggered Idelalisib Interruption and Dose Reduction on Clinical Outcomes in Patients With Relapsed/Refractory B-Cell Malignancies.
Ma S; Chan RJ; Gu L; Xing G; Rajakumaraswamy N; Ruzicka BB; Wagner-Johnston ND
Clin Lymphoma Myeloma Leuk; 2021 May; 21(5):e432-e448. PubMed ID: 33516721
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]